<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00374166</url>
  </required_header>
  <id_info>
    <org_study_id>DFI5880</org_study_id>
    <nct_id>NCT00374166</nct_id>
  </id_info>
  <brief_title>An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder</brief_title>
  <official_title>An Eight-week, Multicenter, Double-blind, Placebo- and Paroxetine-controlled Study Evaluating the Efficacy and Tolerability of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) in Outpatients With Generalized Anxiety Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to evaluate the efficacy and safety of two doses of SSR149415 (250 mg and
      100 mg twice daily) compared to placebo and paroxetine 20 mg once daily in outpatients with
      generalized anxiety disorder
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to Day 56 in the 14-item Hamilton Anxiety Rating Scale (HAM-A) total score.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Day 56 in the Clinical Global Impression (CGI) Severity of Illness score.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">325</enrollment>
  <condition>Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>SSR149415 - 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SSR149415 250 mg, twice daily for a maximum of 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SSR149415 - 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SSR149415 100 mg and additional placebo capsules in order that all patients are being administered three capsules twice daily for a maximum of 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paroxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paroxetine 20 mg and additional placebo capsules in order that all patients are being administered three capsules twice daily for a maximum of 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for a maximum of 9 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSR149415</intervention_name>
    <description>Oral administration (capsules of 50 and 100 mg)</description>
    <arm_group_label>SSR149415 - 250 mg</arm_group_label>
    <arm_group_label>SSR149415 - 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration (capsules)</description>
    <arm_group_label>SSR149415 - 100 mg</arm_group_label>
    <arm_group_label>Paroxetine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine</intervention_name>
    <description>Oral administration (capsules)</description>
    <arm_group_label>Paroxetine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of generalized anxiety disorder, as defined by Diagnostic and Statistical
             Manual of Mental Disorders, 4th Edition (DSM-IV) criteria and confirmed by the
             semi-structured Mini International Neuropsychiatric Interview (MINI) General Anxiety
             Disorder (GAD) Plus Module.

        Exclusion Criteria:

          -  Total score of less than 22 on the (Hamilton Anxiety rating scale)HAM-A.

          -  Montgomery-Asberg Depression Rating Scale (MADRS) total score greater than 17.

          -  Patients with a current history (within 6 months) of major depressive disorder or
             history or presence of bipolar disorders or psychotic disorders.

          -  Patients with alcohol dependence or abuse or substance dependence or abuse in the past
             12 months except nicotine or caffeine dependence.

          -  Patients who have used the following prior to entry into Acute Phase: antipsychotics
             within 3 months, antidepressants including Monoamine oxidase inhibitors (MAOIs) within
             1 month, anxiolytics within 2 weeks, mood-stabilizer (lithium, anticonvulsants) within
             1 month, and/or high dose or prolonged benzodiazepine (continuous use for 3 months
             prior to admission) use.

        The investigator will evaluate whether there are other reasons why a patient may not
        participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2006</study_first_submitted>
  <study_first_submitted_qc>September 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2006</study_first_posted>
  <disposition_first_submitted>April 26, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>April 26, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 25, 2016</disposition_first_posted>
  <last_update_submitted>April 26, 2016</last_update_submitted>
  <last_update_submitted_qc>April 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-anxiety agents</keyword>
  <keyword>antidepressive agents</keyword>
  <keyword>controlled clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

